SEC Form 4 · accession 0001181431-15-008322
Adverum Biotechnologies, Inc. · ADVM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Linda Bain
Officer — Chief Financial Officer
Period of report
Jun 12, 2015
Accepted (ET)
Jun 15, 2015 · 5:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001501756
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 12, 2015 | M | 3,500 | $3.15 | A | 12,500 | D | |
| Common StockF2 | Jun 12, 2015 | S | 3,500 | $39.9414 | D | 9,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $3.15 | Jun 12, 2015 | M | 3,500 | D | — | Apr 21, 2024 | Common Stock | 3,500 | 233,000 | D |
Explanation of responses
- F1Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
- F2This transaction was executed in multiple trades in prices ranging from $39.8100 to $40.1900, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3Twenty-five percent (25%) of the shares subject to the option vested and became exercisable on the first anniversary measured from April 14, 2014, and the remaining shares subject to the option vest in 36 successive, equal installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.